When the dust settles, Lucentis/Avastin will IMO end up being part of the SoC for DME.
In the redesigned trial, MRK should include an arm testing Lucentis/Avastin + I-vation as well as an arm testing Lucentis/Avastin monotherapy; if they don’t, they incur the risk of achieving a successful outcome in the trial that is all but meaningless from a business standpoint.
Market Data 
Markets 
AI
